Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants with end-stage renal disease (ESRD).
Epistemonikos ID: ff9d4a2dee245532c999eac349530b7efcb2f3c2
First added on: May 11, 2024